Ovarian Cancer and Us - best viewed in FIREFOX

Search: this blog, links from posts and the web.....

Loading...

Tuesday, June 08, 2010

detailed ASCO article: Bevacizumab Prolongs Progression-free Survival for Women with Advanced Ovarian Cancers - ASCO (includes chart)




One to 2-Year Surveillance Intervals Reduce Risk of Colorectal Cancer in Families With Lynch Syndrome



Background & Aims
Two percent to 4% of all cases of colorectal cancer (CRC) are associated with Lynch syndrome. Dominant clustering of CRC (non-Lynch syndrome) accounts for 1%–3% of the cases. Because carcinogenesis is accelerated in Lynch syndrome, an intensive colonoscopic surveillance program has been recommended since 1995. The aim of the study was to evaluate the effectiveness of this program.

Conclusions
With surveillance intervals of 1–2 years, members of families with Lynch syndrome have a lower risk of developing CRC than with surveillance intervals of 2–3 years. Because of the low risk of CRC in non-Lynch syndrome families, a less intensive surveillance protocol can be recommended.

Septal Perforation - Medical Aspects: eMedicine Otolaryngology and Facial Plastic Surgery



Septal Perforations



Gastrointestinal perforation: MedlinePlus Medical Encyclopedia



Latest News Releases - ASCO



Note: general link

Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies — Cancer Epidemiology, Biomarkers & Prevention



Conclusion: Anti-MUC1 antibodies evaluated several years before diagnosis may be associated with lower risk of subsequent ovarian cancer in women <64 years old at assessment.

Impact: Key elements of an “immune model” to explain ovarian cancer risk factors are confirmed and should be evaluated in larger prospective studies.

Low-Penetrance Susceptibility Variants in Familial Colorectal Cancer — Cancer Epidemiology, Biomarkers & Prevention